|
|
|
| Clinical effect of Saifurun combined with vitamin B6 in the treatment of patients with hand-foot syndrome caused by Osimertinib |
| GUO Lianying1 LI Jiuqiang2 WANG Jumei1 |
1.Department of Oncology, Handan Central Hospital, Hebei Province, Handan 056001, China;
2.Department of Pain, the Third Hospital of Handan, Hebei Province, Handan 056001, China |
|
|
|
Abstract Objective To explore the clinical effect of Saifurun combined with vitamin B6 in the treatment of patients with hand-foot syndrome (HFS) caused by Osimertinib. Methods A total of 114 patients with HFS due to oral Osimertinib admitted to Handan Central Hospital of Hebei Province from January 2017 to June 2019 were selected and divided into control group and observation group according to random number table method, with 57 patients in each group. The control group was given vitamin B6 orally, 100 mg/time, three times per day. Based on the control group, the observation group was applied with Saifurun on hands and feet, two to three drops per time, four times per day. During the treatment period, both groups still received oral Osimertinib Mesylate, 80 mg/time, once a day. After six months of treatment, the HFS grading and the improvement rate of quality of life were observed in the two groups, and the quantitative symptom score changes before and after treatment were compared between the two groups. Results After six months of treatment, the HFS grading of the observation group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05). After six months of treatment, the quantitative symptom scores of erythema edema and desiccated skin in both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P ＜ 0.05). The improvement rate of quality of life in the observation group was higher than that in the control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Saifurun combined with vitamin B6, it can improve the symptoms of HFS caused by Osimertinib and improve the quality of life of patients.
|
|
|
|
|
|
[1] 张爽，王艳.奥希替尼治疗非小细胞肺癌的研究进展[J].现代肿瘤医学，2019，27（13）：2395-2398.
[2] 韩梅，葛明，刘月娥.阿帕替尼致手足综合征临床及文献病例分析[J].药物不良反应杂志，2020，22（4）：233-238.
[3] Karimi E，Gharib B，Rostami N，et al. Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome [J]. J Herb Med，2019，42（8）：17-18.
[4] 朱孝娟，李杰.参草手足润肤膏治疗手足综合征随机双盲对照试验临床观察[J].中华中医药杂志，2019，34（8）：3825-3828.
[5] 孙勇生，谢长生.抗肿瘤药物引致手足综合征的中西医诊疗进展[J].肿瘤学杂志，2018，24（3）：271-277.
[6] 于然，娄彦妮，贾立群.手足皮肤反应患者生活质量量表汉化及信效度分析[J].中国中西医结合皮肤性病学杂志，2020，19（2）：142-144.
[7] 郭婷，何虹，胡丰阳，等.复方黄柏液治疗卡培他滨所致手足综合征的疗效观察[J].中华中医药杂志，2019，34（6）：2829-2832.
[8] 王丹丹，陈伟贤，夏文晋，等.脾多肽联合化疗治疗乳腺癌的临床疗效观察[J].中国现代医学杂志，2017，27（3）：93-96.
[9] Gerber PA，Duschner N，Homey B，et al. Brimonidine tartrate 0.33% gel for the prevention and management of hand-foot syndrome [J]. J Dtsch Dermatol Ges，2019，17（5）：552-554.
[10] 笪美红，史美祺，严翘，等.阿法替尼皮肤不良反应及其与疗效的相关性分析[J].中华皮肤科杂志，2021，54（1）：64-67.
[11] Li FF，Hong C，Li GS. Chemotherapy-induced hand-foot syndrome in rectal cancer treated with acupuncture [J]. World J Acupunct Moxibustion，2018，32（14）：221-225.
[12] 王俊镔，张晶，卢冬彦，等.阿帕替尼联合经导管肝动脉灌注化疗栓塞治疗中晚期肝癌临床研究的系统评价[J].安徽医药，2019，23（12）：2504-2510.
[13] 刘楠，吴秀伟，李烦繁，等.安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析[J].国际肿瘤学杂志，2019，46（3）：147-152.
[14] 赵德华，王继生，楚明明，等.抗肿瘤药物引起手足综合征的机制及防治措施[J].中国现代应用药学，2019，36（11）：1437-1442.
[15] 董雪.盐酸多柔比星脂质体所致手足综合征的临床管理进展[J].中国肿瘤临床与康复，2020，27（3）：128-130.
[16] 罗方英.赛肤润在压疮高危人群中的临床应用[J].医学临床研究，2018，35（1）：177-178.
[17] 梁丽花，王秀琼，李雅琴.赛肤润联合美皮康治疗老年患者压疮的疗效观察[J].海南医学，2017，28（7）：1170-1172.
[18] 陈丽霞，闫峰.雷火灸联合维生素B6治疗卡培他滨化疗所致手足综合征的临床研究[J].山东中医药大学学报，2020，44（6）：674-678.
[19] Liu Y，May BH，Zhang AL，et al. Integrative Herbal Med-icine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer：A Systematic Review and Meta-Analysis [J]. Integr Cancer Ther，2019，18（21）：223-225.
[20] 叶芃，李迎春，于凤媛.中药沐足在奥沙利铂化疗所致手足综合征患者中的应用[J].中国当代医药，2020，27（13）：227-229.
[21] 金振兴，杜秀平.盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察[J].临床与病理杂志，2020，40（4）：905-912.
[22] 郭连英，李九强，王菊美.赛肤润在小分子靶向药所致手足综合征中的应用[J].临床医药文献电子杂志，2020， 7（23）：12.
[23] 彭雪，杨文博，张寒，等.抗肿瘤药物诱导的手足综合征的诊疗进展[J].现代肿瘤医学，2019，27（8）：1461-1464.
[24] Jandu H，Church D，Paul J，et al. Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine [J]. Ann Oncol，2019，30（S4）：1253-1257.
[25] 王文明，段爱雄，江启安，等.多西他赛伊立替康联合替吉奥用于晚期胃癌患者的疗效对比[J].河北医学，2020， 26（1）：158-161.
[26] 王晨奇.赛肤润液体敷料对卡培他滨致手足综合征的效果观察[J].医药前沿，2017，7（5）：230-232. |
|
|
|
